摘要
目的:评价硫氮卓酮治疗冠心病严重心衰伴哮喘的长期疗效和安全性。方法:145例冠心病严重心衰伴哮喘的患者住院后经14d常规抗心衰和抗喘治疗后,随机分为2组,治疗组加用地尔硫卓120mg(72例),对照组用安慰剂(73例),并作了长达一年以上的远期随访。随访结束时复查了6分步行试验,生活质量,心电图,超声心动图等。结果:硫氮卓酮组6分步行距离增加,生活质量改善,心肌缺血改善,肺动脉压下降(P均<0.01),保持治疗 8周时的水平。随访结束时,硫氮卓酮组死亡 24例(33.3％),对照组死亡38例(52.0％),P>0.001。硫氮卓酮组再住院19例(26.4％),对照组再住院27例(40.0％),P<0.05,并且无明显的不良反应发生。结论:硫氮卓酮长期治疗能改善冠心病严重心衰伴哮喘的心肌缺血,降低肺动脉压,减少死亡率与再住院率,安全性高。
Objective: The aim of study was to ascertain safety and efficacy of long - term diltiazem
therapy on severe ischemic heart failure with asthma.Methods: Methods: A randomized double blind con-
trolled study about ditiazem in 145 patients with severe IHF and asthma was performed from Jau 1999 to
feb 2003 .All aptients had received conventional CHF and asthma therapy for two weeks and randomly bi-
vided into cliltiazem group (Dil 120mg/day n = 72 ) and placebo group (Pla n = 73 )
. Sex. age. symptoms. NYHA class, degree of asthma and Minnesota Living with heart failure score were
similar in the two groups.Mean time of follow - up was 27 months (more than 6 months in all patients)
. Results: There was a significant difference in mortality between two groups (24 in Dil group vs 38 in Pla
group P<0 .001 ), MLWHF score in end of fellow - up in Dil groups was lower than that in Pla group
without apparent side effects. Conclusions: Long - term diltiazem therapy may be safety and decrease mor-
tality in patients with severe IHF with asthma.
出处
《黔南民族医专学报》
2004年第1期9-11,共3页
Journal of Qiannan Medical College for Nationalities
关键词
冠心病
严重心衰
哮喘
生活质量
硫氮卓酮
ischemic heart failure
asthma
mortality
diltiazem quality of life
